Full case includes Shepard's, Headnotes, Legal Analytics from Lex Machina, and more.
773 F.3d 1186 *; 2014 U.S. App. LEXIS 22737 **; 112 U.S.P.Q.2D (BNA) 1945 ***
PAR PHARMACEUTICAL, INC., AND ALKERMES PHARMA IRELAND LIMITED, Plaintiffs-Appellants, v. TWI PHARMACEUTICALS, INC., Defendant-Appellee.
Subsequent History: On remand at, Injunction granted at Par Pharm., Inc. v. TWi Pharms., Inc., 2015 U.S. Dist. LEXIS 28147 (D. Md., Mar. 9, 2015)
On remand at, Findings of fact/conclusions of law at Par Pharm., Inc. v. TWi Pharms., Inc., 120 F. Supp. 3d 468, 2015 U.S. Dist. LEXIS 97977 (D. Md., 2015)
Injunction denied by Par Pharm., Inc. v. TWi Pharms., Inc., 2015 U.S. Dist. LEXIS 99326 (D. Md., July 30, 2015)
Motion denied by, Costs and fees proceeding at Par Pharm., Inc. v. TWi Pharms., Inc., 2016 U.S. Dist. LEXIS 133009 (D. Md., Sept. 27, 2016)
Prior History: [**1] Appeal from the United States District Court for the District of Maryland in No. 1:11-cv-02466-CCB, Judge Catherine C. Blake.
Par Pharms., Inc. v. TWi Pharms., Inc., 2014 U.S. Dist. LEXIS 21704 (D. Md., Feb. 21, 2014)
Disposition: VACATED AND REMANDED.
megestrol, district court, prior art, food, patients, nanoparticle, technology, motivation, combine, patent, variability, skill, interpatient, unexpected, bioavailability, micronized, limitations, invention, nanosized, teaches, particle, viscosity, formulations, elimination, absorption, invalid, reasonable expectation, summary judgment, objective indicia, weight gain
Patent Law, Nonobviousness, Evidence, Fact & Law Issues, Elements & Tests, General Overview, Prima Facie Obviousness, Jurisdiction & Review, Standards of Review, Clearly Erroneous Review, De Novo Review, Anticipation & Novelty, Accidental Anticipation & Inherency, Prior Art